DSDouglas R. Seals

Douglas R. Seals

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Douglas R. Seals has a total of 369 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early women’s health research on endurance exercise training and cardiovascular aging at the University of Colorado Boulder using the masters athlete model

    by Douglas R. Seals, Christopher A. DeSouza, Hirofumi Tanaka, Kerrie L. Moreau, Sanna Darvish, Charlie Ambrose, Kevin P. Davy

    In 1993, we initiated research at the University of Colorado Boulder to determine the effects of endurance exercise training on healthy cardiovascular aging in women. To do so, we leveraged the vibrant local community of female masters runners as a model to systematically demonstrate for the first time the broad physiological and healthy benefits of endurance training for maintaining optimal levels of aerobic capacity, cardiovascular function, and cardiovascular risk factors in women throughout the lifespan.


  • Open Access

    Integrated Multiomics Links Metabolic and Inflammatory Remodeling to Arterial Stiffness After the 4,486-km Trans Europe Footrace

    by Christopher M Clements, CeAnn C Udovich, Katelyn R Ludwig, Francesca Cendali, Monika Dzieciatkowska, Sotirios P Fortis, Uwe H Schütz, Arno Schmidt-Trucksäss, Christopher Klenk, Angelo D’ALessandro, et al.

    Rationale: Regular aerobic exercise protects against vascular aging and reshapes the circulating molecular milieu, but the relation between vascular function, circulating molecules, and exercise dose at extreme volumes remains poorly defined. The vascular and molecular consequences of chronic, multi-stage ultra-endurance running are particularly unclear. Objective: To define circulating molecular signatures associated with vascular dysfunction following the 64-stage, 4,486-km Trans Europe Foot Race (TEFR). Methods and Results: Integrated multiomics analysis (proteomics, lipidomics, metabolomics) of plasma from 27 finishers revealed a coordinated systemic shift driving an oxidative phenotype. Specifically, we identified altered arginine metabolism and a universal upregulation of lipotoxic ceramides consistent with incomplete fatty acid oxidation. In conjunction, we identified upregulation of innate immune system pathways including the acute phase response and the complement system. Central pulse wave velocity (cPWV) increased significantly after the race, consistent with arterial stiffening. To test whether the post-race circulating milieu could directly influence vascular mechanics, naïve murine aortic rings were incubated with participant plasma. Post-race plasma acutely increased aortic elastic modulus, and this effect was attenuated by the superoxide dismutase mimetic TEMPOL, supporting a ROS-dependent component. In human aortic endothelial cells (HAECs), post-race plasma increased reactive oxygen species generation without detectable changes in eNOS phosphorylation, total eNOS abundance, or stimulated nitric oxide production. Endothelial ROS responses were associated with components of the terminal complement pathway. Conclusions: Extreme multi-stage ultra-endurance exercise induces a distinct systemic milieu associated with arterial stiffening through ROS-sensitive mechanisms. This response is characterized by remodeling of arginine-related metabolism, ceramide accumulation, innate immune activation, and oxidative stress, without evidence of reduced measured eNOS abundance or stimulated NO production. These findings identify candidate molecular pathways linking prolonged metabolic stress to vascular dysfunction.

  • Open Access

    Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long‐Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab‐Based Chemotherapy

    by João E. Izaias, Artur O. Sales, Bruna E. Ono, Thais S. Rodrigues, Gabrielly M. P. S. Silva, Priscilla S. Pentagna, Andre L. P. Albuquerque, Flavia N. Folchini, Fernanda M. C. Colombo, Maria C. C. Irigoyen, et al.

    Background: Long‐term survivors of breast cancer (BC) treated with doxorubicin and trastuzumab‐based chemotherapy are at increased risk of developing cardiovascular disease. However, the physiological mechanisms associated with increased cardiovascular disease risk are completely unknown. We hypothesized that long‐term survivors of BC, compared with controls, exhibit sympathetic neural hyperactivity, vascular dysfunction, cardiac morphofunctional changes, exercise intolerance, and alterations in the circulating milieu. Methods: Twenty‐three survivors of BC (age: 48.9±1.3 years; body mass index: 25.2±0.8 kg/m 2 ) and 18 (age: 46.4±1.3 years; body mass index: 26.8±0.8 kg/m 2 ) well‐matched controls were studied. Muscle sympathetic nerve activity (microneurography), brachial artery flow‐mediated dilation (ultrasound‐Doppler), carotid‐femoral pulse wave velocity (tonometry), left ventricular ejection fraction and global longitudinal strain (echocardiography), peak oxygen uptake (cardiopulmonary exercise testing), endothelial cell‐derived extracellular vesicles (flow cytometry), and plasma metabolome (mass spectrometry) were assessed. Complementary experiments were conducted on human umbilical vein endothelial cells cultured with plasma samples from subjects. Results: Survivors of breast cancer were tested ⁓8 years after cancer treatment completion. Muscle sympathetic nerve activity was higher and brachial artery flow‐mediated dilation and peak oxygen uptake were lower in survivors than controls. Survivors of breast cancer exhibited higher circulating endothelial cell‐derived extracellular vesicles, higher reactive oxygen species bioactivity, and lower acetylcholine‐evoked nitrics oxide production in plasma‐treated human umbilical vein endothelial cells. Twenty‐eight plasma metabolites differed in survivors versus controls. Peak oxygen uptake was inversely related to muscle sympathetic nerve activity or positively to brachial artery flow‐mediated dilation. No differences in carotid‐femoral pulse wave velocity, left ventricular ejection fraction, and left ventricular global longitudinal strain were observed. Conclusions: Our findings demonstrate that long‐term survivors of breast cancer exhibit sympathetic overdrive, vascular dysfunction, and exercise intolerance, which may contribute to increased cardiovascular disease risk in this population.


  • Top Cited Papers

    Late-Onset Menopause Attenuates Aortic Stiffness in the Postmenopausal Period

    by Sanna Darvish, Kevin O. Murray, Sophia A. Mahoney, Nicholas S. VanDongen, Melanie C. Zigler, Charlie Ambrose, Martinique A. Flickinger, Julie A. Reisz, Angelo D’ALessandro, Kristen L. Nowak, et al.

    BACKGROUND: A later age at menopause (≥55 years) is associated with lower cardiovascular disease risk compared with a normal age at menopause (45–54 years) in postmenopausal women (PMW). Aortic stiffening increases cardiovascular disease risk, but the impact of late-onset menopause on aortic stiffness is unknown. METHODS: Total aortic stiffness (carotid-femoral pulse wave velocity [PWV CF ]) was measured in 40 late-onset and 86 normal-onset PMW. Structural- and load/blood pressure-dependent PWV CF were calculated with exponential models; the percent of total PWV CF attributable to each was determined. Elastic modulus was assessed in aortic rings from female C57BL/6 N mice (3–6 months) exposed to 5% PMW serum. Lipidomics and triglyceride-related metabolite exposure of aortas with/without the mitochondrial antioxidant MitoQ identified lipid drivers of mitochondrial reactive oxygen species-related stiffness. RESULTS: PWV CF was 128 cm/s lower in late-onset (835±24 cm/s) versus normal-onset (963±24 cm/s) PMW. The difference in PWV CF remained >100 cm/s in multivariable models adjusted for age and education, cardiovascular disease risk factors, and medication use. Systolic and diastolic blood pressure were 10 and 6 mmHg lower in late-onset PMW. Some (CF in late-onset PMW was related to lower load-dependent PWV CF . However, the majority (≈85%) was attributable to lower structural-dependent PWV CF . Elastic modulus was 35% lower in aortas exposed to serum from late- versus normal-onset PMW because of less mitochondrial reactive oxygen species-dependent stiffness. Triglyceride (16:0) was a driver of the effects of serum. CONCLUSIONS: Our findings suggest attenuated aortic stiffening via lower structural-dependent factors may be one mechanism by which late-onset menopause lowers cardiovascular disease risk.


  • Cellular senescence mediates doxorubicin chemotherapy-induced vascular endothelial dysfunction: translational evidence of prevention with senolytic treatment

    by Ravinandan Venkatasubramanian, Sophia A. Mahoney, David A. Hutton, Nicholas S. VanDongen, Vienna E. Brunt, Nathan T. Greenberg, Abigail G. Longtine, Lukas Brandt, Andreas M. Beyer, Simon Melov, et al.

    We demonstrate that cellular senescence contributes to doxorubicin-related vascular endothelial dysfunction and establishes efficacy for the use of senolytic therapy to improve vascular function following doxorubicin administration. Mechanistically, we found that cellular senescence reduced NO bioavailability and promoted excessive production of vascular mitochondrial superoxide-related oxidative stress, both of which were prevented with senolytic therapy. We translated these findings to humans and showed that ex vivo exposure to doxorubicin impaired arteriole endothelial function, which was prevented with senolytic exposure.


  • Cellular Senescence Mediates Doxorubicin Chemotherapy-Induced Aortic Stiffening: Role of Glycation Stress

    by Ravinandan Venkatasubramanian, Mary A. Darrah, Sophia A. Mahoney, David A. Hutton, Grace S. Maurer, Katelyn R. Ludwig, Nicholas S. Van Dongen, Nathan T. Greenberg, Abigail G. Longtine, Vienna E. Brunt, et al.

    BACKGROUND: Mechanisms underlying doxorubicin chemotherapy-induced aortic stiffening are incompletely understood. To determine the role of cellular senescence and the senescence-associated secretory phenotype (SASP) in mediating doxorubicin-induced aortic stiffening and the influence of senolytic therapy. METHODS: Aortic stiffness (aortic pulse wave velocity) and associated mechanisms were assessed in young adult p16-3MR mice, a model that allows for genetic-based clearance of senescent cells with ganciclovir. Young (4–6 months) mice were injected with doxorubicin and subsequently treated with ganciclovir or the senolytic ABT263. We evaluated the influence of SASP-associated circulating factors in plasma (the circulating SASP milieu) in mediating aortic stiffening ex vivo (aortic elastic modulus) and examined the contribution of glycation stress. RESULTS: Doxorubicin increased aortic pulse wave velocity (425±6 versus control, 353±5 cm/s; P P P =0.02 versus plasma from control mice), whereas plasma from doxorubicin-ganciclovir and doxorubicin-ABT263 groups did not. Glycation stress was implicated in SASP-mediated aortic stiffening with doxorubicin, as inhibition of receptor-mediated glycation stress signaling attenuated plasma-induced aortic stiffening. CONCLUSIONS: Cellular senescence and the circulating SASP milieu contribute to doxorubicin-induced aortic stiffening. Senolytics hold promise for preserving aortic stiffening following doxorubicin exposure.


  • Open Access

    Senolytic treatment with fisetin reverses age-related endothelial dysfunction partially mediated by SASP factor CXCL12

    by Sophia A. Mahoney, Krystyna Mazan-Mamczarz, Dimitrios Tsitsipatis, Nicholas S. VanDongen, Charnae’ Henry-Smith, Ada N. Okereke, Rachel Munk, Sanna Darvish, Kevin O. Murray, Supriyo De, et al.

    Background: Advancing age is the strongest risk factor for cardiovascular diseases (CVDs), primarily due to progressive vascular endothelial dysfunction. Cellular senescence and the senescence-associated secretory phenotype (SASP) contribute to age-related endothelial dysfunction by promoting mitochondrial oxidative stress and inflammation, which reduce nitric oxide (NO) bioavailability. However, the molecular changes in senescent endothelial cells and their role in endothelial dysfunction with aging remain incompletely unclear. As such, in this study we sought to identify the endothelial cell senescence-related signalling pathways, endothelial-derived SASP factors, and their impact on endothelial function with aging. Methods: Single-cell transcriptomics was performed on aortas from young (6 months) and old (27 months) mice with and without in vivo senolytic treatment with fisetin (100 mg/kg/day administered in an intermittent dosing paradigm) to characterize endothelial cell senescence and transcript expression changes. Circulating levels of SASP factors were measured to validate transcriptional changes. Plasma exposure and protein addition and inhibiton experiments were conducted in isolated mouse arteries and cultured human endothelial cells to determine the causal role of the circulating SASP milieu and specific SASP factors in mediating endothelial dysfunction and underlying mechanisms-of-action. Results: Senescent endothelial cells exhibited elevated expression of SASP factors, particularly Cxcl12 , which was reversed by fisetin supplementation, with responses also reflected in circulating CXCL12 concentrations. Plasma from old mice impaired endothelial function by inducing vascular cell senescence, reducing NO, increasing mitochondrial oxidative stress, and promoting endothelial-to-mesenchymal transition—effects partially driven by CXCL12 and prevented by fisetin. Conclusions: These results identify the SASP and CXCL12 as drivers of age-related endothelial dysfunction and establish mechanisms of senolytic intervention with fisetin supplementation. NOVELTY AND SIGNFICANCE: What is known?: Advancing age is the primary risk factor for cardiovascular disease, in part due to progressive endothelial dysfunction. Cellular senescence contributes to age-related endothelial impairment through the secretion of a pro-inflammatory milieu known as the senescence-associated secretory phenotype (SASP), which can affect neighboring cells and tissue function. Senolytic compounds selectively eliminate senescent cells and improve vascular function in preclinical models of aging. What new information does this article contribute?: Endothelial cells are highly susceptible to senescence with aging in vivo and are selectively cleared by senolytic treatment with the natural compound fisetin. Single-cell transcriptomic profiling identifies CXCL12 as the most highly upregulated SASP factor in senescent endothelial cells and in circulation with aging, both of which are reversed by senolytic treatment with fisetin. We identify a specific circulating SASP factor, CXCL12, as a partial mediator of endothelial dysfunction by inducing mitochondrial oxidative stress, impairing nitric oxide bioavailability, and promoting endothelial-to-mesenchymal transition (Endo, which is restored by senolytic treatment with fisetin. Summary: This study provides novel mechanistic insight into how senescent endothelial cells and their secretory products—particularily CXCL12—contribute to age-related endothelial dysfunction. It further demonstrates that senolytic treatment with fisetin reverses these effects, highlighting a promising translational strategy for targeting vascular aging and preserving endothelial health. GRAPHICAL


  • Sex-specific effects of mild kidney dysfunction on vascular function in midlife and older adults

    by Sanna Darvish, McKinley E. Coppock, Kevin O. Murray, Daniel H. Craighead, Michel Chonchol, Kristen L. Nowak, Douglas R. Seals, Matthew J. Rossman

    Midlife/older (ML/O) adults with mild kidney dysfunction (MKD) are at an increased CVD risk compared with ML/O adults with normal kidney function. We assessed whether ML/O men and postmenopausal women with MKD exhibit vascular dysfunction compared with ML/O adults without MKD. We observed MKD-related vascular dysfunction in men but not in women. Thus, vascular dysfunction may contribute to MKD-associated increases in CVD risk in men but is unlikely to contribute to the increased risk in postmenopausal women.


  • Sympathetic neural overdrive, vascular dysfunction, and diminished exercise capacity in patients with long COVID-19: a long-term study of cardiovascular sequelae

    by Bruna E. Ono, João E. Izaias, Artur O. Sales, Thais S. Rodrigues, Camila S. Nunes, Jéssica F. Niec, Natália G. Rocha, Helena N. M. Rocha, Gabriel F. Texeira, Amanda G. Rodrigues, et al.

    Patients with long COVID, even 2 yr after SARS-CoV-2 infection, exhibited sympathetic neural overdrive, aortic stiffening, endothelial dysfunction, cardiac morphofunctional changes, diminished aerobic exercise capacity, increased circulating endothelial cell-derived EVs, decreased antioxidant activity, and increased oxidant activity. Moreover, we showed that the reduced aerobic exercise capacity was associated with sympathetic neural outflow, vascular dysfunction, cardiac morphofunctional alterations, and increased circulating oxidative stress.


  • Open Access

    Effects of aerobic exercise of different intensities on the social, emotional, and financial functioning of healthy older adults: results from a 16-week exercise randomized control trial

    by Charleen J. Gust, Renée Martin-Willett, Laurel P. Gibson, Gregory Giordano, Douglas R. Seals, Angela D. Bryan

    Better social, emotional, and financial functioning are associated with improved health outcomes in older adults. While the literature supports a positive relationship between physical activity and increased functional ability in older adulthood, the intensity of physical activity necessary to achieve these gains remains uncertain. To address this gap, the current analysis uses data collected as part of a larger randomized controlled trial to examine the effects of a supervised exercise intervention on measures of social, emotional, and financial functioning. Healthy older adults ( n = 211) completed baseline assessments including cardiovascular fitness and health and functioning measures and were randomly assigned to 16 weeks of either: (1) low intensity continuous training (LICT); or (2) moderate intensity continuous training + interval training (MICT + IT). Participants across exercise conditions reported a significant decrease from baseline to post-intervention in depression [ F (1, 158) = 22.17, p < .001] and instrumental risk taking [ F (1, 157) = 6.72, p < .05]. Further, participants assigned to the MICT + IT condition showed significantly greater improvements in loneliness relative to those in the LICT condition [ F (1, 157) = 5.99, p < .05]. By and large, healthy older adults experienced some improvements in functional ability after 16 weeks of exercise. Though most changes were not related to the intensity of exercise condition, associations between increased cardiovascular fitness and both depression and anxiety suggest that exercising at an intensity that improves fitness may confer greater benefits in some domains. Trial registration: ClinicalTrials.gov, NCT02068612.